Antibodies

2 April 2016

Samsung Bioepis’ Flixabi® Infliximab Biosimilar Recommended for Approval in the European Union

2 April 2016

CHMP Issues a Positive Opinion on Janssen’s Single-Agent DARZALEX® (daratumumab)

2 April 2016

Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) for Treatment of Advanced Melanoma

1 April 2016

Sanofi and Regeneron Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients

1 April 2016

Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain

31 March 2016

Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma

31 March 2016

ArmaGen Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial in Brazil to Study AGT-181 for the Treatment of Hurler Syndrome

31 March 2016

Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II

31 March 2016

First Phase 3 Trial of Daratumumab in Combination with Standard Therapy in Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint in Planned Interim Analysis

31 March 2016

European Medicines Agency Validates Bristol-Myers Squibb’s Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients

31 March 2016

Daiichi Sankyo Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment

29 March 2016

Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine

24 March 2016

UCB Announces Results from First Head-to-Head study of Cimzia® (certolizumab pegol) and Humira® (adalimumab) in Bio-Naïve Rheumatoid Arthritis Patients

23 March 2016

Teva Announces FDA Approval of CINQAIR® (reslizumab) Injection

23 March 2016

Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy

23 March 2016

Lilly’s Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

22 March 2016

Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial in cancer patients

22 March 2016

Immune Pharmaceuticals Announces Publication of Preclinical Data in Support of Its Bispecific Antibody Platform in The Journal of Immunology

22 March 2016

Janssen Announces the Initiation of Two Studies Evaluating Daratumumab (DARZALEX®) and Atezolizumab in Multiple Myeloma and Solid Tumor

22 March 2016

New Data Presented at European Crohn’s and Colitis Organisation (ECCO) Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment

21 March 2016

MabVax Therapeutics Initiates Phase I Trial of HuMab-5B1 for Treatment of Pancreatic Cancer

21 March 2016

Elusys Therapeutics receives FDA approval for Anthim® (obiltoxaximab) injection for the treatment and prophylaxis of inhalational anthrax

21 March 2016

Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis

18 March 2016

STELARA® Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn’s Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy

18 March 2016

Celltrion Healthcare: Switching to Remsima®▼ (infliximab) from originator has no negative effect on safety or efficacy in 10 real-world studies

17 March 2016

OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)

17 March 2016

IgM Concentrate: Remarkable relative reduction in mortality of more than 50% in subgroup of patients

16 March 2016

Bird Rock Bio’s Gerilimzumab, an Anti-IL-6 Antibody, Demonstrates Potential for Affordable Global Access to a Novel Biologic to Treat Rheumatoid Arthritis

15 March 2016

Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study

15 March 2016

Immunomedics Provides Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients With Advanced Pancreatic Cancer

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CD38-Targeted Antibody & Cell Therapy Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

PSMA-Targeted Therapy Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

CD73 Inhibitor Pipeline Review